Literature DB >> 11110059

Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.

K Smolnikar1, S Löffek, T Schulz, H Michna, P Diel.   

Abstract

Apoptosis induction by the pure antiestrogen faslodex, also known as ICI 182780 (ICI), is associated with an effective down-regulation of Bcl-2 expression in the human breast cancer cell line MCF-7. Recent observations point out that beside members of the Bcl-2 family also the TNFR1 signaling pathway may be involved in apoptosis induction by antiestrogens. In this report we have analyzed the expression of members of the TNFR1 signaling pathway during the apoptotic process induced by the pure antiestrogen faslodex and by tamoxifen (Tam) in MCF-7 breast cancer cells. Treatment with 10(-7) M ICI or 10(-7) M Tam leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. In contrast, Bcl-2 expression was strongly decreased following administration of ICI but only weakly after administration of Tam. Western blot analysis and studies by the use of fluorescence microscopy and flow cytometry revealed a time dependent induction of TNFR1 protein and cell surface expression in MCF-7 cells in response to treatment with ICI. To investigate if TNFR1 is functionally involved in apoptosis induction by antiestrogens, we tested whether TNFR1 blocking antibodies can counteract the growth inhibitory action of Tam and ICI. Coincubation of MCF-7 cells with antiestrogens (ICI or Tam) and blocking TNFR1 antibodies lead to an increase in cell viability. Our results provide evidence for a cross talk between the TNFR1 signaling pathway and antiestrogens during the process of apoptosis induction in MCF-7 breast cancer cells. The superiority of the pure antiestrogen ICI to induce apoptosis in MCF-7 cells may result from its capability to modulate the induction of apoptosis via Bcl-2 as well as TNF-associated signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110059     DOI: 10.1023/a:1006490416408

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells.

Authors:  Simona Caporali; Manami Imai; Lucia Altucci; Massimo Cancemi; Silvana Caristi; Luigi Cicatiello; Filomena Matarese; Roberta Penta; Dipak K Sarkar; Francesco Bresciani; Alessandro Weisz
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

2.  p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells.

Authors:  Cornelia Braicu; Valentina Pileczki; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Mol Cell Biochem       Date:  2013-06-04       Impact factor: 3.396

3.  Methyl jasmonate decreases membrane fluidity and induces apoptosis through tumor necrosis factor receptor 1 in breast cancer cells.

Authors:  Laxmi Yeruva; John Abiodun Elegbede; Stephen W Carper
Journal:  Anticancer Drugs       Date:  2008-09       Impact factor: 2.248

4.  Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin.

Authors:  Laxmi Yeruva; Casey Hall; John Abiodun Elegbede; Stephen W Carper
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

5.  G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells.

Authors:  Akira Ichikawa; Jiro Ando; Koichi Suda
Journal:  Hum Cell       Date:  2008-05       Impact factor: 4.174

Review 6.  Estrogenic or antiestrogenic therapies for multiple myeloma?

Authors:  Brigitte Sola; Jack-Michel Renoir
Journal:  Mol Cancer       Date:  2007-09-24       Impact factor: 27.401

7.  Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients.

Authors:  Steen Knudsen; Thomas Jensen; Anker Hansen; Wiktor Mazin; Justin Lindemann; Irene Kuter; Naomi Laing; Elizabeth Anderson
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.